S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
What is a Gold IRA, and is it a Viable Investment?
What To Do With Your Trades Today (Ad)pixel
Closing prices for crude oil, gold and other commodities
Is Braze Inc Ready To Rocket Higher? 
Did You See These Trend Reversals? (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Canada approves largest telecom deal in country's history
Did You See These Trend Reversals? (Ad)pixel
Medicare, Social Security could fall short over next decade
Elon Musk Denied Meeting with Federal Trade Commission Chair Until Twitter 'Fully' Complies With FTC Requests
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
What is a Gold IRA, and is it a Viable Investment?
What To Do With Your Trades Today (Ad)pixel
Closing prices for crude oil, gold and other commodities
Is Braze Inc Ready To Rocket Higher? 
Did You See These Trend Reversals? (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Canada approves largest telecom deal in country's history
Did You See These Trend Reversals? (Ad)pixel
Medicare, Social Security could fall short over next decade
Elon Musk Denied Meeting with Federal Trade Commission Chair Until Twitter 'Fully' Complies With FTC Requests
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
What is a Gold IRA, and is it a Viable Investment?
What To Do With Your Trades Today (Ad)pixel
Closing prices for crude oil, gold and other commodities
Is Braze Inc Ready To Rocket Higher? 
Did You See These Trend Reversals? (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Canada approves largest telecom deal in country's history
Did You See These Trend Reversals? (Ad)pixel
Medicare, Social Security could fall short over next decade
Elon Musk Denied Meeting with Federal Trade Commission Chair Until Twitter 'Fully' Complies With FTC Requests
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
What is a Gold IRA, and is it a Viable Investment?
What To Do With Your Trades Today (Ad)pixel
Closing prices for crude oil, gold and other commodities
Is Braze Inc Ready To Rocket Higher? 
Did You See These Trend Reversals? (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Canada approves largest telecom deal in country's history
Did You See These Trend Reversals? (Ad)pixel
Medicare, Social Security could fall short over next decade
Elon Musk Denied Meeting with Federal Trade Commission Chair Until Twitter 'Fully' Complies With FTC Requests
OTCMKTS:HKMPY

Hikma Pharmaceuticals - HKMPY Stock Forecast, Price & News

$41.50
-0.05 (-0.12%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$41.50
▼
$41.50
50-Day Range
$40.75
▼
$43.77
52-Week Range
$25.12
▼
$56.77
Volume
497 shs
Average Volume
1,613 shs
Market Capitalization
N/A
P/E Ratio
13.41
Dividend Yield
0.77%
Price Target
N/A

HKMPY stock logo

About Hikma Pharmaceuticals (OTCMKTS:HKMPY) Stock

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.

Receive HKMPY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HKMPY Stock News Headlines

March 19, 2023 | finance.yahoo.com
Hikma Pharmaceuticals Full Year 2022 Earnings: EPS Misses Expectations
February 7, 2023 | uk.investing.com
Hikma Pharmaceuticals PLC (HIK)
April 1, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.
January 31, 2023 | marketwatch.com
Hikma Pharmaceuticals rises Tuesday, outperforms market
January 24, 2023 | marketwatch.com
Hikma Pharmaceuticals falls Tuesday, underperforms market
December 27, 2022 | msn.com
Junshi inks licensing deal with Hikma for toripalimab; FDA filing still under review
December 15, 2022 | marketwatch.com
Hikma Pharmaceuticals rises Thursday, outperforms market
October 9, 2022 | finance.yahoo.com
Hikma Pharmaceuticals PLC (HKMPY)
April 1, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.
September 28, 2022 | reuters.com
HKMPY.PK - | Stock Price & Latest News | Reuters
September 25, 2022 | uk.finance.yahoo.com
Hikma Pharmaceuticals PLC (H5P.F)
August 30, 2022 | finance.yahoo.com
Hikma launches RYALTRIS™ seasonal allergic rhinitis nasal spray in the US
July 17, 2022 | benzinga.com
Hikma Pharmaceuticals (OTC:HKMPY), Analyst Ratings, Price Targets, Predictions
May 14, 2022 | finance.yahoo.com
Investors in Hikma Pharmaceuticals (LON:HIK) have unfortunately lost 26% over the last year
April 21, 2022 | finance.yahoo.com
Hikma completes acquisition of Custopharm
April 20, 2022 | seekingalpha.com
Hikma gets preliminary approval from FTC to acquire Custopharm
April 20, 2022 | finance.yahoo.com
Hikma confirms FTC preliminary approval for Custopharm
April 19, 2022 | finance.yahoo.com
U.S. FTC approves Hikma deal for Custopharm with conditions
February 27, 2022 | finance.yahoo.com
Analysts Have Made A Financial Statement On Hikma Pharmaceuticals PLC's (LON:HIK) Yearly Report
November 9, 2021 | finance.yahoo.com
Those who invested in Hikma Pharmaceuticals (LON:HIK) five years ago are up 62%
October 22, 2021 | finance.yahoo.com
Hikma donates 50,000 doses of injectable naloxone to help expand non-profit access to lifesaving treatment for reversing opioid overdoses
September 27, 2021 | finance.yahoo.com
Hikma Bolsters Injectable Portfolio With $375M Custopharm Acquisition
September 27, 2021 | finance.yahoo.com
Hikma strengthens US Injectables business through acquisition of Custopharm
July 7, 2021 | finance.yahoo.com
Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 25% Discount?
June 21, 2021 | finance.yahoo.com
U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents
June 21, 2021 | finance.yahoo.com
UPDATE 1-U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents
April 21, 2021 | finance.yahoo.com
Hikma Pharmaceuticals PLC -- Moody's withdraws Hikma's ratings for business reasons
See More Headlines
Receive HKMPY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HKMPY Company Calendar

Ex-Dividend for 5/15 Dividend
3/23/2023
Today
4/01/2023
Dividend Payable
5/15/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:HKMPY
CUSIP
N/A
CIK
N/A
Web
www.hikma.com
Phone
442073992760
Fax
N/A
Employees
8,700
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
13.41
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Said Samih Taleb Darwazah
    Executive Chairman & Chief Executive Officer
  • Khalid Walid Hosni Nabilsi
    Chief Financial Officer
  • Mazen Samih Taleb Darwazah
    Executive Vice Chairman & President-MENA Region
  • Majda Labadi
    Executive VP-Organizational Development
  • Riad Mishlawi
    President-Injectables Division

Key Competitors

View All Competitors













HKMPY Stock - Frequently Asked Questions

How have HKMPY shares performed in 2023?

Hikma Pharmaceuticals' stock was trading at $36.95 at the beginning of 2023. Since then, HKMPY shares have increased by 12.3% and is now trading at $41.50.
View the best growth stocks for 2023 here.

Are investors shorting Hikma Pharmaceuticals?

Hikma Pharmaceuticals saw a decrease in short interest in February. As of February 15th, there was short interest totaling 2,300 shares, a decrease of 14.8% from the January 31st total of 2,700 shares. Based on an average daily volume of 1,400 shares, the days-to-cover ratio is presently 1.6 days.
View Hikma Pharmaceuticals' Short Interest.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals declared a dividend on Friday, March 17th. Shareholders of record on Friday, March 24th will be paid a dividend of $0.72 per share on Monday, May 15th. This represents a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, March 23rd. This is a boost from the stock's previous dividend of $0.36.
Read our dividend analysis for HKMPY.

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals (OTCMKTS:HKMPY) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.65%. The dividend payout ratio is 10.34%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for HKMPY.

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPY."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HKMPY stock can currently be purchased for approximately $41.50.

How many employees does Hikma Pharmaceuticals have?

The company employs 8,700 workers across the globe.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The official website for the company is www.hikma.com. The company can be reached via phone at 442073992760.

This page (OTCMKTS:HKMPY) was last updated on 4/1/2023 by MarketBeat.com Staff